Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events

BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines

Read more at globenewswire.com